(PRWEB) January 12, 2005
The traditional line between research-based pharmaceutical companies and the growing generics industry is rapidly fading. More and more companies that straddle that changing boundary are beginning to understand and appreciate the benefits of a mixed portfolio. As generic companies begin moving up the value chain to higher priced products, the pharma giants are increasingly exploring the potential of the fast-growing biogenerics industry.
Biogenerics: Challenges and Promise, a new report from Arrowhead Publishers, takes an insightful look at the burgeoning biogenerics industry.
The report analyzes how the generics industry will be shaped by the global healthcare market and regulatory developments over the next five years.
The international biogenerics market faces a multitude of challenges. Biogenerics: Challenges and Promise will assesses those challenges and analyzes the potential for maximizing the myriad opportunities available in this competitive and dynamic industry. The report also appraises and compares current and emerging biogeneric products and identifies those with the most potential for growth.
Key questions answered in this report:
ÂWho are the major players in the biogenerics arena and what kind of impact are they making on the industry?
ÂWhat obstacles stand in the way of a smooth transition from biopharmaceutical manufacture to biogenerics?
ÂHow has the lack of a clear framework impeded the industryÂs progress in producing and distributing biogeneric drugs? And how will these issues be resolved?
ÂWhat specific hurdles must biogeneric manufacturers maneuver in order to get their products on the market?
This new Arrowhead report contains:
ÂThorough analysis of the drivers of and restraints on the biogenerics market
ÂDetailed information and analysis concerning groundbreaking biogeneric regulation in the US and Europe.
ÂIdentification of key biopharmaceuticals at risk for biogeneric competition
ÂIn-depth profiles of leading pharmaceutical companies involved in the biogenerics industry
ÂAnalytical discussions which integrate regulatory issues with market activity
and company activity
# # #